Food and Drug Administration Safety and Innovation Act
http://dbpedia.org/resource/Food_and_Drug_Administration_Safety_and_Innovation_Act an entity of type: MusicalWork
The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration (FDA) the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also creates the breakthrough therapy designation program and extends the priority review voucher program to make eligible rare pediatric diseases. The measure was passed by 96 senators voting for and one voting against.
rdf:langString
rdf:langString
Food and Drug Administration Safety and Innovation Act
xsd:integer
37238447
xsd:integer
1112328084
rdf:langString
through
rdf:langString
Tom Harkin
xsd:date
2012-05-15
rdf:langString
Senate
rdf:langString
Food and Drug Administration Safety and Innovation Act
xsd:date
2012-07-09
xsd:integer
112
rdf:langString
The Food and Drug Administration Safety and Innovation Act of 2012 (FDASIA) is a piece of American regulatory legislation signed into law on July 9, 2012. It gives the United States Food and Drug Administration (FDA) the authority to collect user fees from the medical industry to fund reviews of innovator drugs, medical devices, generic drugs and biosimilar biologics. It also creates the breakthrough therapy designation program and extends the priority review voucher program to make eligible rare pediatric diseases. The measure was passed by 96 senators voting for and one voting against.
rdf:langString
An Act to amend the Federal Food, Drug, and Cosmetic Act to revise and extend the user-fee programs for prescription drugs and medical devices, to establish user-fee programs for generic drugs and biosimilars, and for other purposes.
xsd:nonNegativeInteger
24666